Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Rhea-AI Summary
Altimmune (Nasdaq: ALT) will report its third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. ET the same day to discuss results and provide a business update.
The live webcast will be available on Altimmune’s Investor Relations website and requires registration to receive dial-in numbers and a unique PIN. A replay of the call will be posted on the Investor Relations site and remain available for up to three months.
Positive
- None.
Negative
- None.
News Market Reaction 7 Alerts
On the day this news was published, ALT gained 1.75%, reflecting a mild positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $375M at that time.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025.
Altimmune management will host a conference call at 8:30 a.m. ET on November 6 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Elliot Fox
Real Chemistry
efox@realchemistry.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) report Q3 2025 results and hold its conference call?
How can I access the Altimmune (ALT) live webcast for the November 6, 2025 call?
Do I need to register to join the Altimmune (ALT) conference call on November 6, 2025?
Will a replay of Altimmune’s (ALT) November 6, 2025 conference call be available?
What will Altimmune (ALT) management discuss on the November 6, 2025 call?
